GlassScriptPhysician profile
Mathew W Stephens
NPI 1487438529
$3,772.31
in general payments reported to CMS, 2019-2025
31 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $223 · 2024: $1,287 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,772.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.63 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $722.02 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $229.50 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.84 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $219.85 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $193.88 | 2025 | Rybelsus, Ozempic, Wegovy |
| Madrigal Pharmaceuticals | $181.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $93.36 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $84.57 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $75.75 | 2023-2025 | Repatha, Evenity, Otezla |
| Corcept Therapeutics | $71.03 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $67.60 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $60.86 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $60.81 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.27 | 2024-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $57.23 | 2024-2025 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.01 | 2023-2024 | Caplyta |
| Axsome Therapeutics, INC. | $53.09 | 2024-2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $52.54 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $48.71 | 2023-2024 | Spravato |
| Lundbeck LLC | $40.38 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $40.21 | 2024-2025 | Ponvory, Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $39.12 | 2023-2024 | Quviviq |
| Tandem Diabetes Care, INC. | $34.86 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mylan Specialty L.P. | $30.95 | 2024 | Yupelri |
| Boston Scientific Corporation | $29.91 | 2025 | General - Pain Management |
| Glaxosmithkline, LLC. | $29.28 | 2024 | Arexvy, Trelegy Ellipta |
| Collegium Pharmaceutical, INC. | $18.37 | 2025 | Jornay Pm |
| Neurelis, INC. | $17.12 | 2024 | Valtoco |
| Verity Pharmaceuticals INC. | $15.40 | 2025 | Tlando |
| Phathom Pharmaceuticals, INC. | $15.10 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.